UBS Reiterates a 'Buy' on Gilead Sciences (GILD); Raises Numbers on Favorite Large-Cap Biotech
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $67.03 +0.12%
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
UBS reiterates a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $65.00 (from $61.00).
Analyst, Matthew Roden, updates his model (raises PT and estimates) following Stribild's approval, a competitor's failure (Bristol-Myer's (NYSE: BMY) BMS-094). Overall, Roden, sees HIV and HCV product cycles as underappreciated.
Current, Roden's model is 12% above consensus for 2014 revenues, seeing HIV sales ($650M delta) and GS-7977 sales ($500M delta). He cites the Stribild price, with is 33% above Artipla. For HCV, Roden thinks his $1.1B GS-7977 estimate (consensus is $600M) is actually conservative, considering Incivek did $951M in its first six months of sales.
For FY12, EPS estimate raised slightly from $3.90 to $3.91 an FY13 from $4.50 to $4.53.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.76 yesterday.
Analyst, Matthew Roden, updates his model (raises PT and estimates) following Stribild's approval, a competitor's failure (Bristol-Myer's (NYSE: BMY) BMS-094). Overall, Roden, sees HIV and HCV product cycles as underappreciated.
Current, Roden's model is 12% above consensus for 2014 revenues, seeing HIV sales ($650M delta) and GS-7977 sales ($500M delta). He cites the Stribild price, with is 33% above Artipla. For HCV, Roden thinks his $1.1B GS-7977 estimate (consensus is $600M) is actually conservative, considering Incivek did $951M in its first six months of sales.
For FY12, EPS estimate raised slightly from $3.90 to $3.91 an FY13 from $4.50 to $4.53.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Upgrades Adidas AG (ADS:GR) (ADDYY) to Buy
- Temenos AG (TEMN:SW) (TMSNY) PT Lowered to CHF58 at Barclays
- EDP Renovaveis SA (EDPR:LI) (EDRVF) PT Lowered to EUR16 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
